Shiyi Yu1, Xue Gong1, Zhifang Ma1, Meng Zhang1, Ling Huang1, Jun Zhang1, Shuang Zhao2, Tao Zhu3, Zhenghong Yu4, Liming Chen1. 1. Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Science, Nanjing Normal University, Nanjing, 210023, People's Republic of China. 2. Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing, 210002, People's Republic of China. 3. Institute of Immunology and CAS Key Laboratory of Innate Immunity and Chronic Disease, Innovation Center for Cell Biology, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, 230027, People's Republic of China. 4. Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing, 210002, People's Republic of China. 13327800182@189.cn.
Abstract
PURPOSE: Endocrine therapy is the most commonly used approach for the treatment of estrogen receptor (ERα)-positive breast cancer. The cure rate of patients with ERα-positive breast cancer is, however, limited due to the occurrence of endocrine resistance. Loss of ERα is one major mechanism for the occurrence of endocrine resistance. Recent studies have shown that pan-HDAC inhibitors may be effective in reversing endocrine resistance. However, the molecular mechanism underlying this reversal has remained largely unknown. Here we aimed to unravel this mechanism. METHODS: Endocrine resistant breast cancer cell lines were established through exposure to tamoxifen. mRNA expression was assessed by qRT-PCR and protein expression by Western blotting. The effect of HDAC3 inhibition on the viability of endocrine resistant breast cancer cells was evaluated using CCK-8 and colony forming assays. Immunohistochemistry was used to detect protein expression in primary breast cancer tissues. RESULTS: We found that in endocrine resistant breast cancer cells loss of ERα led to HDAC3 stabilization via decreased ERα-mediated caspase7 expression, resulting in reduced caspase7-mediated HDAC3 cleavage. We also found that the ERα-caspase7-HDAC3 axis determined the global H3K9 and H4K16 acetylation status, which was positively correlated with ERα expression. Finally, we found that inhibition of HDAC3 significantly decreased the viability of endocrine resistant breast cancer cells exhibiting ERα deficiency. The ERα-caspase7-HDAC3 axis was subsequently verified in primary endocrine resistant breast cancer samples. CONCLUSIONS: From our data we conclude that the ERα-caspase7-HDAC3 axis may play a role in promoting the proliferation of endocrine resistant breast cancer cells. HDAC3 may serve as a therapeutic target for (a subset of) endocrine resistant breast cancers exhibiting ERα loss.
PURPOSE: Endocrine therapy is the most commonly used approach for the treatment of estrogen receptor (ERα)-positive breast cancer. The cure rate of patients with ERα-positive breast cancer is, however, limited due to the occurrence of endocrine resistance. Loss of ERα is one major mechanism for the occurrence of endocrine resistance. Recent studies have shown that pan-HDAC inhibitors may be effective in reversing endocrine resistance. However, the molecular mechanism underlying this reversal has remained largely unknown. Here we aimed to unravel this mechanism. METHODS:Endocrine resistant breast cancer cell lines were established through exposure to tamoxifen. mRNA expression was assessed by qRT-PCR and protein expression by Western blotting. The effect of HDAC3 inhibition on the viability of endocrine resistant breast cancer cells was evaluated using CCK-8 and colony forming assays. Immunohistochemistry was used to detect protein expression in primary breast cancer tissues. RESULTS: We found that in endocrine resistant breast cancer cells loss of ERα led to HDAC3 stabilization via decreased ERα-mediated caspase7 expression, resulting in reduced caspase7-mediated HDAC3 cleavage. We also found that the ERα-caspase7-HDAC3 axis determined the global H3K9 and H4K16 acetylation status, which was positively correlated with ERα expression. Finally, we found that inhibition of HDAC3 significantly decreased the viability of endocrine resistant breast cancer cells exhibiting ERα deficiency. The ERα-caspase7-HDAC3 axis was subsequently verified in primary endocrine resistant breast cancer samples. CONCLUSIONS: From our data we conclude that the ERα-caspase7-HDAC3 axis may play a role in promoting the proliferation of endocrine resistant breast cancer cells. HDAC3 may serve as a therapeutic target for (a subset of) endocrine resistant breast cancers exhibiting ERα loss.
Entities:
Keywords:
Breast cancer; Endocrine resistance; Epigenetic modification; H3K9ac; H4K16ac; HDAC3; Loss of ERα expression; caspase7
Authors: Yanning Ma; Yongfang Yue; Min Pan; Jie Sun; Jue Chu; Xiaoying Lin; Wenxia Xu; Lifeng Feng; Yan Chen; Dingwei Chen; Vivian Y Shin; Xian Wang; Hongchuan Jin Journal: Am J Cancer Res Date: 2015-01-15 Impact factor: 6.166
Authors: H Kurokawa; A E Lenferink; J F Simpson; P I Pisacane; M X Sliwkowski; J T Forbes; C L Arteaga Journal: Cancer Res Date: 2000-10-15 Impact factor: 12.701
Authors: Mark Kirschbaum; Paul Frankel; Leslie Popplewell; Jasmine Zain; Maria Delioukina; Vinod Pullarkat; Deron Matsuoka; Bernadette Pulone; Arnold J Rotter; Igor Espinoza-Delgado; Auayporn Nademanee; Stephen J Forman; David Gandara; Edward Newman Journal: J Clin Oncol Date: 2011-02-07 Impact factor: 44.544
Authors: Grazia Arpino; Stephanie J Green; D Craig Allred; Dannika Lew; Silvana Martino; C Kent Osborne; Richard M Elledge Journal: Clin Cancer Res Date: 2004-09-01 Impact factor: 12.531
Authors: Matthew Brentnall; Luis Rodriguez-Menocal; Rebeka Ladron De Guevara; Enrique Cepero; Lawrence H Boise Journal: BMC Cell Biol Date: 2013-07-09 Impact factor: 4.241